IMMX/ 03/25/2026 · 8:26 AM Morgan Stanley Bullish on Immix Biopharma: Sees $1B+ Opportunity for NXC-201 CAR-T Therapy Morgan Stanley initiated coverage on Immix Biopharma with an Overweight rating and $20 price target.
